• Q1 financial performance: Biocon recorded 10% revenue growth, 10.5% EBITDA growth, and a 10 basis point margin improvement, driven by biopharma momentum and balance sheet deleveraging.
• Interest cost reduction: Interest expenses fell 22% on a constant-currency basis from approximately ₹284 crore to ₹214 crore following the retirement of all investor-held structured debt.
• Generics segment growth: Generics revenue grew 22% year-on-year during the quarter, supported by core base business performance, operating leverage, pricing, and API growth.
• GLP-1 expansion strategy: Targeting a projected $140 billion GLP-1 market by 2030, Biocon has established full end-to-end integration across active pharmaceutical ingredients, drug product filling, and pen injectors, with meaningful revenue contributions expected in future quarters.